WO2008078728A1 - Ascorbic acid-containing pharmaceutical composition - Google Patents

Ascorbic acid-containing pharmaceutical composition Download PDF

Info

Publication number
WO2008078728A1
WO2008078728A1 PCT/JP2007/074783 JP2007074783W WO2008078728A1 WO 2008078728 A1 WO2008078728 A1 WO 2008078728A1 JP 2007074783 W JP2007074783 W JP 2007074783W WO 2008078728 A1 WO2008078728 A1 WO 2008078728A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
ascorbic acid
containing pharmaceutical
azelnidipine
olmesartan medoxomil
Prior art date
Application number
PCT/JP2007/074783
Other languages
French (fr)
Japanese (ja)
Inventor
Shuichi Yada
Mitsuru Kanno
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Priority to JP2008551106A priority Critical patent/JPWO2008078728A1/en
Publication of WO2008078728A1 publication Critical patent/WO2008078728A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is pharmaceutical composition having improved dissolution property, which contains olmesartan medoxomil and azelnidipine. Specifically disclosed is a pharmaceutical composition containing (A) olmesartan medoxomil, (B) azelnidipine and (C) ascorbic acid or a salt thereof.
PCT/JP2007/074783 2006-12-26 2007-12-25 Ascorbic acid-containing pharmaceutical composition WO2008078728A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008551106A JPWO2008078728A1 (en) 2006-12-26 2007-12-25 Ascorbic acid-containing pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-349472 2006-12-26
JP2006349472 2006-12-26

Publications (1)

Publication Number Publication Date
WO2008078728A1 true WO2008078728A1 (en) 2008-07-03

Family

ID=39562517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074783 WO2008078728A1 (en) 2006-12-26 2007-12-25 Ascorbic acid-containing pharmaceutical composition

Country Status (3)

Country Link
JP (1) JPWO2008078728A1 (en)
TW (1) TW200833325A (en)
WO (1) WO2008078728A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014224099A (en) * 2013-04-15 2014-12-04 株式会社三和化学研究所 Olmesartan medoxomil-containing pharmaceutical composition

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508128A (en) * 1991-05-15 1994-09-14 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー Novel composition of angiotensin-2 receptor antagonist and calcium channel blocker
JPH0753373A (en) * 1993-06-07 1995-02-28 Takeda Chem Ind Ltd Agent for prevention or treatment of angiotensin ii-mediated diseases
WO2002034263A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Preventives/remedies for portal hypertension
WO2004067003A1 (en) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2006123766A1 (en) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Film coated preparation containing dextrose
WO2006123765A1 (en) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Film coated preparation
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508128A (en) * 1991-05-15 1994-09-14 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー Novel composition of angiotensin-2 receptor antagonist and calcium channel blocker
JPH0753373A (en) * 1993-06-07 1995-02-28 Takeda Chem Ind Ltd Agent for prevention or treatment of angiotensin ii-mediated diseases
WO2002034263A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Preventives/remedies for portal hypertension
WO2004067003A1 (en) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2006123766A1 (en) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Film coated preparation containing dextrose
WO2006123765A1 (en) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Film coated preparation
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAPAN PHARMACEUTICAL EXCIPIENTS COUNCIL: "Iyakuhin Tenkabutsu Jiten", vol. 1ST ED., 1994, KABUSHIKI KAISHA YAKUJI NIPPOSHA HAKKO, pages: 2 - 3 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014224099A (en) * 2013-04-15 2014-12-04 株式会社三和化学研究所 Olmesartan medoxomil-containing pharmaceutical composition

Also Published As

Publication number Publication date
TW200833325A (en) 2008-08-16
JPWO2008078728A1 (en) 2010-04-30

Similar Documents

Publication Publication Date Title
AU2007299727A8 (en) Self preserved aqueous pharmaceutical compositions
IL199397A (en) Heterocyclic compounds, pharmaceutical compositions comprising them and medical uses thereof
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2010032875A3 (en) Heterocyclic carboxamide compounds
WO2008115281A3 (en) Compounds for treating viral infections
WO2008022974A3 (en) Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof
WO2007122581A3 (en) Compositions and kits of phenylephrine
WO2009150118A3 (en) Novel salts of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid
CL2007000918A1 (en) COMPOUNDS DERIVED FROM ENFUMAFUNGINA, INHIBITORS OF (1,3) -BETA-D-GLUCANOSINTETASE; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT A FUNGICAL INFECTION.
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
DE502007005902D1 (en) -METHYL-19-NOR-20-SPIROX-4-EN-3-ONE), as well as the PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
ZA200900237B (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
WO2008009750A3 (en) Macrocyclic compounds useful as bace inhibitors
WO2010013835A3 (en) Solid pharmaceutical composition
BRPI1008356A2 (en) "Udenafil acid addition salt, its preparation method and pharmaceutical composition"
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan
TW200800993A (en) Organic compounds
WO2008009802A3 (en) Drugs comprising an inhibitor of class 1 alpha mannosidase for the treatment of sarcoglycanopathies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860012

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008551106

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07860012

Country of ref document: EP

Kind code of ref document: A1